Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (2)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
Thailand (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
STADA acquires UK branded product company Natures Aid
STADA receives “positive opinion” from the EMA for teriparatide biosimilar
STADA records further growth in the first nine months of 2016 – Adjusted net income of at least Euro 180 million now expected for full year …
STADA lays the groundwork for sustainable growth
STADA: Sebastian Krämer-Bach to take on responsibility for expanded Corporate Communications
STADA: Leslie Iltgen is the new Vice President Investor Relations
STADA Annual General Meeting: Executive Board presents updated strategy, confirms outlook for financial year 2016 – five new members elected…
STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board
STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board
STADA: Excellent business development in the first six months of 2016 – reported and adjusted key earnings figures significantly above previ…
STADA announces agenda for the Annual General Meeting 2016
STADA approves growth targets for 2019: adjusted Group sales Euro 2.6 billion, adjusted EBITDA Euro 510 million and adjusted net income Euro…
Important step on the path to reconfiguring the STADA Supervisory Board
Change in Chief Executive Officer at STADA Arzneimittel AG
STADA begins process for significant renewal of its Supervisory Board
STADA: Significant renewal of Supervisory Board brought forward by two years – Annual General Meeting 2016 postponed to August 26, 2016
STADA: STADA allows elaborated motion from Active Ownership Fund as supplement to the Annual General Meeting 2016
STADA: First quarter of 2016 better than expected – reported key earnings figures substantially higher than previous year – very strong deve…
STADA: Successful refinancing through the securing of additional promissory note loans of a total of Euro 350 million
STADA: Development in 2015 as expected under difficult framework conditions – dividend to increase – outlook for 2016 confirmed
STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published
STADA: Appointment of Dr. Matthias Wiedenfels extended